Clinical Trial Update: Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Sipuleucel-T with immediate versus delayed CTLA-4 blockade in prostate cancer has completed with results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CTLA-4 blockade (CTLA-4 inhibitor)
• sipuleucel-T (sipuleucel-T)

Snippet

Sponsor: University of California, San Francisco | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-01-25